44,077 Shares in Alto Neuroscience, Inc. $ANRO Bought by AdvisorShares Investments LLC

AdvisorShares Investments LLC bought a new position in Alto Neuroscience, Inc. (NYSE:ANRO) during the fourth quarter, HoldingsChannel reports. The firm bought 44,077 shares of the company’s stock, valued at approximately $785,000.

Other large investors also recently modified their holdings of the company. Northwestern Mutual Wealth Management Co. raised its position in Alto Neuroscience by 14,567.0% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 212,672 shares of the company’s stock valued at $3,786,000 after buying an additional 211,222 shares during the last quarter. Geode Capital Management LLC raised its position in Alto Neuroscience by 20.8% in the 4th quarter. Geode Capital Management LLC now owns 287,435 shares of the company’s stock valued at $5,118,000 after buying an additional 49,535 shares during the last quarter. AlphaCore Capital LLC raised its position in Alto Neuroscience by 100.0% in the 4th quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock valued at $356,000 after buying an additional 10,000 shares during the last quarter. Torren Management LLC purchased a new stake in Alto Neuroscience in the 4th quarter valued at $62,000. Finally, Armistice Capital LLC raised its position in Alto Neuroscience by 0.7% in the 3rd quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock valued at $6,577,000 after buying an additional 12,000 shares during the last quarter.

Key Stories Impacting Alto Neuroscience

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and a $50 price target, suggesting the firm still sees meaningful upside from current levels. ANRO stock page
• Positive Sentiment: Alto Neuroscience appointed Andrew Miller, Ph.D., founder of Karuna Therapeutics, to its Board of Directors, a move that could strengthen strategic and clinical development oversight. Board appointment article
• Neutral Sentiment: The company’s most recent quarterly earnings missed expectations, which continues to frame investor focus on losses and the pace of execution. Earnings page
• Negative Sentiment: HC Wainwright cut FY2026 EPS estimates to ($2.98) from ($2.75), reinforcing the view that Alto may remain deeply unprofitable in the near term. Estimate update
• Negative Sentiment: The analyst also lowered forecast EPS for Q2 2026, Q3 2026, Q4 2026, and several 2027-2030 periods, including FY2027 to ($4.39) and FY2028 to ($4.81), which may weigh on sentiment. Multiple estimate cuts

Alto Neuroscience Stock Down 0.5%

Shares of NYSE ANRO opened at $20.12 on Friday. Alto Neuroscience, Inc. has a 52 week low of $2.15 and a 52 week high of $28.44. The business has a 50-day simple moving average of $22.99 and a two-hundred day simple moving average of $19.08. The company has a quick ratio of 20.52, a current ratio of 20.52 and a debt-to-equity ratio of 0.07. The company has a market cap of $706.16 million, a P/E ratio of -8.31 and a beta of 1.62.

Alto Neuroscience (NYSE:ANRO) last issued its earnings results on Wednesday, May 13th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.24). Research analysts anticipate that Alto Neuroscience, Inc. will post -3.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ANRO. BTIG Research increased their price target on Alto Neuroscience from $27.00 to $28.00 and gave the company a “buy” rating in a research report on Tuesday, February 17th. Wedbush increased their price target on Alto Neuroscience from $21.00 to $24.00 and gave the company a “neutral” rating in a research report on Thursday, May 14th. JonesTrading lowered their price target on Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating for the company in a research report on Thursday, April 2nd. Wall Street Zen lowered Alto Neuroscience from a “hold” rating to a “strong sell” rating in a research report on Sunday, May 17th. Finally, Wolfe Research initiated coverage on Alto Neuroscience in a research report on Friday, May 22nd. They set an “outperform” rating for the company. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $35.25.

Alto Neuroscience Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.